10 results about "Pharmaceutical Dose Form" patented technology

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

The invention relates to a pharmaceutical dosage form for oral administration comprising (i) an intragranular phase, which comprises Sertraline or a physiologically acceptable salt thereof; one or more intragranular fillers (preferably selected from one or more sugar alcohols or sugars; preferably mannitol or lactose, more preferably mannitol); one or more intragranular antioxidants (preferably selected from butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), tocopherol or derivatives thereof, ascorbic acid or derivatives thereof, sodium metabisulphite, propyl gallate, sodium thiosulphate, or any combination thereof, more preferably ascorbic acid); (ii) an extragranular phase, which comprises one or more extragranular fillers (preferably mannitol, microcrystalline cellulose, lactose, or any combination thereof); and (iii) optionally, a film coating. The invention further relates to a process for manufacture by wet granulation, wherein the antioxidant is preferably dissolved in the granulation liquid.

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

The utility model discloses a kind of be applied to the comminuting device of crude drug, including base, control mechanism is installed in the upper portion of base, the control mechanism is connected with comminuting mechanism;Motor drive screw feeder feeds and comminutes to the comminuting mechanism.The control mechanism includes the control box being installed in the upper portion of base, switch is arranged on the control box, for starting or closing the comminuting mechanism;It also includes external frequency converter and control system, the frequency converter and the control system are connected with the comminuting mechanism and the control box by communication module or cable.The product granularity of device after grinding is finer, smallest can make material evenly reach 200 microns, can improve drug dissolution rate and bioavailability, enhance preparation uniformity and stability, expand drug dosage form and application range, can satisfy the demand of different customer groups, increase product added value and its sales volume.

Described are continuous manufacturing methods using 3D printing or any similar additive manufacturing technology to produce pharmaceutical dosage forms or pharmaceutical delivery devices. Manufacturing methods using hot-melt extrusion to fabricate filaments for fused deposition modeling (FDM) based 3D printing are disclosed. Methods using FDM based 3D printing to fabricate printed products suitable for pharmaceutical delivery purposes are disclosed. The printed products may have various shapes and configurations.

The present invention relates to a water-soluble film having a mometasone furoate content adjusted to a pH in the range of 3.5 to 5.0. The correspondingly adjusted pH increases the stability of the active ingredient without substantially impairing the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing films of the above type in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can especially be used for treating eosinophilic esophagitis.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

The present invention relates to a liquid pharmaceutical cetrolix composition comprising a stabilizer selected from the group consisting of poloxamer having an average molecular weight of 7,000-12,000 g / mol and / or benzyl alcohol, and a pharmaceutical dosage form comprising the liquid pharmaceutical composition, and their use in inhibiting premature luteinizing hormone surge in a woman undergoing controlled ovarian stimulation. Furthermore, a method for preparing a liquid pharmaceutical cetrolix composition and a pharmaceutical dosage form is disclosed.

The application belongs to the technical field of biological medicine, and provides application of ferulic acid in preparation of a photolysis inhibitor of tigecycline and minocycline. The ferulic acid can significantly inhibit degradation of tigecycline or minocycline under light conditions, and further enhance the antibacterial activity of tigecycline or minocycline under light conditions. Compared with the treatment of tigecycline alone, the addition of ferulic acid can significantly enhance the treatment effect of tigecycline or minocycline as an external medicine on skin or soft tissue infection, effectively expand the drug dosage form of tigecycline or minocycline, and provide a safer and more reliable drug preparation for the treatment of complex drug-resistant pathogenic bacterial skin or soft tissue infection.